Pfizer's Acquisition of Metsera Isn’t the End of Its Deal-Making Journey, as $6B Remains for Future Investments

Pfizer’s Acquisition of Metsera Isn’t the End of Its Deal-Making Journey, as $6B Remains for Future Investments

Pfizer's Acquisition of Metsera Isn’t the End of Its Deal-Making Journey, as $6B Remains for Future Investments